Amicus Therapeutics/FOLD

$13.70

-0.43%
-
1D1W1MYTD1YMAX

About Amicus Therapeutics

Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.
Ticker
FOLD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
John Crowley
Employees
484
Headquarters
Philadelphia, United States

FOLD Metrics

BasicAdvanced
$4.04B
Market cap
-
P/E ratio
-$0.60
EPS
0.78
Beta
-
Dividend rate

What the Analysts think about FOLD

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 9 analysts.
42.77% upside
High $22.00
Low $16.00
$13.70
Current price
$19.56
Average price target

FOLD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-20.77% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$103.5M
9.52%
Net income
$-21.5M
-50.23%
Profit margin
-20.77%
-54.56%

FOLD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.35%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.19
-$0.18
-$0.15
-$0.07
-
Expected
-$0.13
-$0.15
-$0.12
-$0.08
-$0.06
Surprise
50.36%
22.73%
21.62%
-7.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Amicus Therapeutics stock

Buy or sell Amicus Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing